Complement and cytokine based therapeutic strategies in myasthenia gravis

Journal of Autoimmunity

Volumn 37, Issue 2, 2011, Pages 136-143

  Tüzün, Erdem ^a   Huda, Ruksana ^a   Christadoss, Premkumar ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Autoimmunity; Complement; Cytokine; Experimental autoimmune myasthenia gravis; Myasthenia gravis

Indexed keywords

ALPHA INTERFERON; CD59 ANTIGEN; COBROTOXIN; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C9; COMPLEMENT INHIBITOR; CYTOKINE; DECAY ACCELERATING FACTOR; ETANERCEPT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 18 ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; LYMPHOTOXIN; MANNOSE BINDING LECTIN; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; B LYMPHOCYTE DIFFERENTIATION; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL PROLIFERATION; COMPLEMENT BLOOD LEVEL; COMPLEMENT SYSTEM; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; DISEASE SEVERITY; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; EXTRAOCULAR MUSCLE; GLOMERULUS; HELPER CELL; HUMAN; IMMUNIZATION; LYMPH NODE CELL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MONOCYTE; MUSCLE CELL; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PTOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SERODIAGNOSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STROMA CELL; SURVIVAL; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; THYMUS; UPREGULATION;

ANIMALS; AUTOANTIBODIES; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; MICE; MOLECULAR TARGETED THERAPY; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; TH17 CELLS;

EID: 80052668260     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2011.05.006     Document Type: Review

References (99)

1. Vincent A., Drachman D.B. Myasthenia gravis. Adv Neurol 2002, 88:159-188.
2. Conti-Fine B.M., Milani M., Kaminski H.J. Myasthenia gravis: past, present, and future. J Clin Invest 2006, 116:2843-2854.
3. Christadoss P., Poussin M., Deng C. Animal models of myasthenia gravis. Clin Immunol 2000, 94:75-87.
4. Tüzün E., Scott B.G., Goluszko E., Higgs S., Christadoss P. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol 2003, 171:3847-3854.
5. Conti-Fine B.M., Milani M., Wang W. CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann N Y Acad Sci 2008, 1132:193-209.
6. Childs L.A., Harrison R., Lunt G.G. Complement-mediated muscle damage produced by myasthenic sera. Ann N Y Acad Sci 1987, 505:180-193.
7. Engel A.G., Sahashi K., Fumagalli G. The immunopathology of acquired myasthenia gravis. Ann N Y Acad Sci 1981, 377:158-174.
8. Drachman D.B., Adams R.N., Stanley E.F., Pestronk A. Mechanisms of acetylcholine receptor loss in myasthenia gravis. J Neurol Neurosurg Psychiatry 1980, 43:601-610.
9. Tarr J., Eggleton P. Immune function of C1q and its modulators CD91 and CD93. Crit Rev Immunol 2005, 25:305-330.
10. Zachrau B., Finke D., Kropf K., Gosink H.J., Kirchner H., Goerg S. Antigen localization within the splenic marginal zone restores humoral immune response and IgG class switch in complement C4-deficient mice. Int Immunol 2004, 16:1685-1690.
11. Nastuk W.L., Plescia O.J., Osserman K.E. Changes in serum complement activity in patients with myasthenia gravis. Proc Soc Exp Biol Med 1960, 105:177-184.
12. Sahashi K., Engel A.G., Lambert E.H., Howard F.M. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 1980, 39:160-172.
13. Engel A.G., Lambert E.H., Howard F.M. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 1977, 52:267-280.
14. Romi F., Kristoffersen E.K., Aarli J.A., Gilhus N.E. The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo. J Neuroimmunol 2005, 158:191-194.
15. Liu A., Lin H., Liu Y., Cao X., Wang X., Li Z. Correlation of C3 level with severity of generalized myasthenia gravis. Muscle Nerve 2009, 40:801-808.
16. Tüzün E., Saini S.S., Ghosh S., Rowin J., Meriggioli M.N., Christadoss P. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromuscul Disord 2006, 16:137-143.
17. Tüzün E., Scott B.G., Yang H., Wu B., Goluszko E., Guigneaux M., et al. Circulating immune complexes augment severity of antibody-mediated myasthenia gravis in hypogammaglobulinemic RIIIS/J mice. J Immunol 2004, 172:5743-5752.
18. Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008, 131:1940-1952.
19. Yang H., Wu B., Tüzün E., Saini S.S., Li J., Allman W., et al. A new mouse model of autoimmune ocular myasthenia gravis. Invest Ophthalmol Vis Sci 2007, 48:5101-5111.
20. Lennon V.A., Seybold M.E., Lindstrom J.M., Cochrane C., Ulevitch R. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med 1978, 147:973-983.
21. Piddlesden S.J., Jiang S., Levin J.L., Vincent A., Morgan B.P. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol 1996, 71:173-177.
22. Biesecker G., Gomez C.M. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J Immunol 1989, 142:2654-2659.
23. Zhou Y., Gong B., Lin F., Rother R.P., Medof M.E., Kaminski H.J. Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol 2007, 179:8562-8567.
24. Soltys J., Kusner L.L., Young A., Richmonds C., Hatala D., Gong B., et al. Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol 2009, 65:67-75.
25. Tüzün E., Li J., Saini S.S., Yang H., Christadoss P. Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. J Neuroimmunol 2007, 182:167-176.
26. Pták J., Lochman J. Immunoadsorption therapy and complement activation. Transfus Apheresis Sci 2005, 32:263-267.
27. Christadoss P. C5 gene influences the development of murine myasthenia gravis. J Immunol 1988, 140:2589-2592.
28. Chamberlain-Banoub J., Neal J.W., Mizuno M., Harris C.L., Morgan B.P. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol 2006, 146:278-286.
29. Liang S., Krauss J.L., Domon H., McIntosh M.L., Hosur K.B., Qu H., et al. The C5a receptor impairs IL-12-dependent clearance of Porphyromonas gingivalis and is required for induction of periodontal bone loss. J Immunol 2011, 186:869-877.
30. Qi H., Tüzün E., Allman W., Saini S.S., Penabad Z.R., Pierangeli S., et al. C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis. J Neuroimmunol 2008, 196:101-106.
31. Rødgaard A., Nielsen F.C., Djurup R., Somnier F., Gammeltoft S. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol 1987, 67:82-88.
32. Tüzün E., Saini S.S., Yang H., Alagappan D., Higgs S., Christadoss P. Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis. J Neuroimmunol 2006, 174:157-167.
33. Li J., Qi H., Tüzün E., Allman W., Yilmaz V., Saini S.S., et al. Mannose-binding lectin pathway is not involved in myasthenia gravis pathogenesis. J Neuroimmunol 2009, 208:40-45.
34. Nataf S., Carroll S.L., Wetsel R.A., Szalai A.J., Barnum S.R. Attenuation of experimental autoimmune demyelination in complement-deficient mice. J Immunol 2000, 165:5867-5873.
35. Kaminski H.J., Li Z., Richmonds C., Lin F., Medof M.E. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp Neurol 2004, 189:333-342.
36. Kaminski H.J., Kusner L.L., Richmonds C., Medof M.E., Lin F. Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Exp Neurol 2006, 202:287-293.
37. Morgan B.P., Chamberlain-Banoub J., Neal J.W., Song W., Mizuno M., Harris C.L. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol 2006, 146:294-302.
38. Tüzün E., Saini S.S., Morgan B.P., Christadoss P. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis. J Neuroimmunol 2006, 181:29-33.
39. Yapici Z., Tüzün E., Altunayoĝlu V., Erdoĝan A., Eraksoy M. High interleukin-10 production is associated with anti-acetylcholine receptor antibody production and treatment response in juvenile myasthenia gravis. Int J Neurosci 2007, 117:1505-1512.
40. Soltys J., Gong B., Kaminski H.J., Zhou Y., Kusner L.L. Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?. Ann N Y Acad Sci 2008, 1132:220-224.
41. Heckmann J.M., Uwimpuhwe H., Ballo R., Kaur M., Bajic V.B., Prince S. A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis. Genes Immun 2010, 11:1-10.
42. Leite M.I., Jones M., Ströbel P., Marx A., Gold R., Niks E., et al. Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 2007, 171:893-905.
43. Poussin M.A., Goluszko E., Franco J.U., Christadoss P. Role of IL-5 during primary and secondary immune response to acetylcholine receptor. J Neuroimmunol 2002, 125:51-58.
44. Deng C., Goluszko E., Tüzün E., Yang H., Christadoss P. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J Immunol 2002, 169:1077-1083.
45. Deng C., Goluszko E., Baron S., Wu B., Christadoss P. IFN-alpha therapy is effective in suppressing the clinical experimental myasthenia gravis. J Immunol 1996, 157:5675-5682.
46. Huang D., Shi F.D., Giscombe R., Zhou Y., Ljunggren H.G., Lefvert A.K. Disruption of the IL-1beta gene diminishes acetylcholine receptor-induced immune responses in a murine model of myasthenia gravis. Eur J Immunol 2001, 31:225-232.
47. Yang H., Tüzün E., Alagappan D., Yu X., Scott B.G., Ischenko A., et al. IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1. J Immunol 2005, 175:2018-2025.
48. Balasa B., Deng C., Lee J., Christadoss P., Sarvetnick N. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. J Immunol 1998, 161:2856-2862.
49. Ostlie N., Milani M., Wang W., Okita D., Conti-Fine B.M. Absence of IL-4 facilitates the development of chronic autoimmune myasthenia gravis in C57BL/6 mice. J Immunol 2003, 170:604-612.
50. Aricha R., Mizrachi K., Fuchs S., Souroujon M.C. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun 2011, 36:135-141.
51. Poussin M.A., Goluszko E., Hughes T.K., Duchicella S.I., Christadoss P. Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR. J Neuroimmunol 2000, 111:152-160.
52. Wang W., Milani M., Ostlie N., Okita D., Agarwal R.K., Caspi R.R., et al. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. J Immunol 2007, 178:7072-7080.
53. Karachunski P.I., Ostlie N.S., Monfardini C., Conti-Fine B.M. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J Immunol 2000, 164:5236-5244.
54. Im S.H., Barchan D., Maiti P.K., Raveh L., Souroujon M.C., Fuchs S. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J 2001, 15:2140-2148.
55. Christadoss P., Goluszko E. Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. J Neuroimmunol 2002, 122:186-190.
56. Goluszko E., Hjelmström P., Deng C., Poussin M.A., Ruddle N.H., Christadoss P. Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis. J Neuroimmunol 2001, 113:109-118.
57. Goluszko E., Deng C., Poussin M.A., Christadoss P. Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis. J Neuroimmunol 2002, 122:85-93.
58. Wang H.B., Li H., Shi F.D., Chambers B.J., Link H., Ljunggren H.G. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis. Int Immunol 2000, 12:1381-1388.
59. Tuzun E., Christadoss P. Targeting classical complement pathway and IL-6. Myasthenia gravis: disease mechanisms and immune intervention 2010, 327-351. Linus Publishing Inc, New York. P. Christadoss (Ed.).
60. Sitaraman S., Metzger D.W., Belloto R.J., Infante A.J., Wall K.A. Interleukin-12 enhances clinical experimental autoimmune myasthenia gravis in susceptible but not resistant mice. J Neuroimmunol 2000, 107:73-82.
61. Wang W., Ostlie N.S., Conti-Fine B.M., Milani M. The susceptibility to experimental myasthenia gravis of STAT6-/- and STAT4-/- BALB/c mice suggests a pathogenic role of Th1 cells. J Immunol 2004, 172:97-103.
62. Zhang G.X., Xiao B.G., Bai X.F., van der Meide P.H., Orn A., Link H. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J Immunol 1999, 162:3775-3781.
63. Balasa B., Deng C., Lee J., Bradley L.M., Dalton D.K., Christadoss P., et al. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J Exp Med 1997, 186:385-391.
64. Mu L., Sun B., Kong Q., Wang J., Wang G., Zhang S., et al. Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis. Immunology 2009, 128. e826-36.
65. Yang H., Zhang Y., Wu M., Li J., Zhou W., Li G., et al. Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile. Inflamm Res 2010, 59:197-205.
66. Kong Q.F., Sun B., Wang G.Y., Zhai D.X., Mu L.L., Wang D.D., et al. BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO. Eur J Immunol 2009, 39:800-809.
67. Masuda M., Matsumoto M., Tanaka S., Nakajima K., Yamada N., Ido N., et al. Clinical implication of peripheral CD4+CD25+regulatory T cells and Th17 cells in myasthenia gravis patients. J Neuroimmunol 2010, 225:123-131.
68. Rowin J., Meriggioli M.N., Tüzün E., Leurgans S., Christadoss P. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 2004, 63:2390-2392.
69. Adikari S.B., Lian H., Link H., Huang Y.M., Xiao B.G. Interferon-gamma-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis. Clin Exp Immunol 2004, 138:230-236.
70. Duan R.S., Adikari S.B., Huang Y.M., Link H., Xiao B.G. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells. Neurobiol Dis 2004, 16:461-467.
71. Meriggioli M.N., Sheng J.R., Li L., Prabhakar B.S. Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis. Ann N Y Acad Sci 2008, 1132:276-282.
72. Xiao B.G., Duan R.S., Zhu W.H., Lu C.Z. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis. Cell Immunol 2006, 241:95-101.
73. Stegall T., Krolick K.A. Myocytes respond to both interleukin-4 and interferon-gamma: cytokine responsiveness with the potential to influence the severity and course of experimental myasthenia gravis. Clin Immunol 2000, 94:133-139.
74. Tüzün E., Li J., Wanasen N., Soong L., Christadoss P. Immunization of mice with T cell-dependent antigens promotes IL-6 and TNF-alpha production in muscle cells. Cytokine 2006, 35:100-106.
75. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 2009, 373:759-767.
76. Spitzer D., Unsinger J., Bessler M., Atkinson J.P. ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. Mol Immunol 2004, 40:911-919.
77. Mitchell T.J., Naughton M., Norsworthy P., Davies K.A., Walport M.J., Morley B.J. IFN-gamma up-regulates expression of the complement components C3 and C4 by stabilization of mRNA. J Immunol 1996, 156:4429-4434.
78. Youinou P., Haralampos M. Moutsopoulos: a lifetime in autoimunity. J Autoimmun 2010, 35:171-175.
79. Juran B.D., Lazaridis K.N. Update on the genetics and genomics of PBC. J Autoimmun 2010, 35:181-187.
80. Mackay I.R., Leskovsek N.V., Rose N.R. The odd couple: a fresh look at autoimmunity and immunodeficiency. J Autoimmun 2010, 35:199-205.
81. Mavragani C.P., Crow M.K. Activation of the type I interferon pathway in primary Sjogren's syndrome. J Autoimmun 2010, 35:225-231.
82. Scheinecker C., Bonelli M., Smolen J.S. Pathogenetic aspects of systemic lupus erythematosus with an emphasis on reglatory T cells. J Autoimmun 2010, 35:269-275.
83. Wiik A.S., Hoier-Madsen M., Forslid J., Charles P., Meyrowitsch J. Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 2010, 35:276-290.
84. Youinou P., Pers J.-O. The international symposium on Sjogren's syndrome in Brest: the "top of the tops" at the "tip of the tips". Autoimmun Rev 2010, 9:589-590.
85. Saraux A. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjogren's syndrome. Autoimmun Rev 2010, 9:589-634.
86. Meroni P.L., Shoenfeld Y. Systemic lupus erythematosus and the SLE galaxy. Autoimmun Rev 2010, 10:1-2.
87. Katz U., Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev 2010, 10:46-50.
88. Andreoli L., Bazzani C., Taraborelli M., Reggia R., Lojacono A., Brucato A., et al. Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges. Autoimmun Rev 2010, 10:51-54.
89. Youinou P., Pers J.-O., Gershwin M.E., Shoenfeld Y. Geo-epidemiology and autoimmunity. J Autoimmun 2010, 34:J163-J167.
90. Hoffmann M.H., Trembleau S., Muller S., Steiner G. Nucleic acid-association autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 2010, 34:J178-J206.
91. Powell J.J., Faria N., Thomas-McKay E., Pele L.C. Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 2010, 34:J226-J233.
92. Maverakis E., Miyamura Y., Bowen M.P., Correa G., Ono Y., Goodarzi H. Light, including ultraviolet. J Autoimmun 2010, 34:J247-J257.
93. Schilder A.M. Wegener's granulomatosis vasculitis and granuloma. Autoimmun Rev 2010, 9:477-482.
94. Tahir M.A., Pramod K., Ansari S.H., Ali J. Current remedies for vitiligo. Autoimmun Rev 2010, 9:516-520.
95. Ansari A.A., Gershwin M.E. Navigating the passage between Charybdis and Scylla: recognizing the achievements of Noel Rose. J Autoimmun 2009, 33:165-169.
96. Mackay I.R. Clustering and commonalities among autoimmune diseases. J Autoimmun 2009, 33:170-177.
97. Chiorini J.A., Cihakova D., Ouellette C.E., Caturegli P. Sjogren syndrome: advances in the pathogenesis from animal models. J Autoimun 2009, 33:190-196.
98. Kong Y.-C.M., Morris G.P., Brown N.K., Yan Y., Flynn J.C., David C.S. Autoimmune thyroiditis: a model uniquely suited to probe regulatory T cell function. J Autoimmun 2009, 33:239-246.
99. Leuschner F., Katus H.A., Kaya Z. Autoimmune myocarditis: past, present and future. J Autoimmun 2009, 33:282-289.